SCHEMBL20914201

SCHEMBL20914201

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nnc(-c2cccnc2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.43
▸ RAB9A P51151 6/20 0.41
▸ LMNA P02545 1/20 0.39
▸ GUSB P08236 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NPY5R Q15761 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ GAA P10253 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ F2 P00734 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914070 0.91 POLB (0.41) NPC1RAB9AALDH1A1POLBKMT2A
SCHEMBL20931250 0.88 LMNA (0.44) LMNAALDH1A1POLBKMT2AMEN1
SCHEMBL20819013 0.86 POLB (0.41) ALDH1A1POLBKMT2AMEN1L3MBTL1
SCHEMBL20914314 0.86 NPC1 (0.43) NPC1RAB9AALDH1A1POLBKMT2A
SCHEMBL20914275 0.85 NPY5R (0.41) LMNAALDH1A1POLBKMT2AMEN1
SCHEMBL20914166 0.85 POLB (0.40) ALDH1A1POLBKMT2AMEN1L3MBTL1
SCHEMBL20914419 0.84 MECP2 (0.45) NPC1RAB9AALDH1A1POLBKMT2A
SCHEMBL20914224 0.84 RAB9A (0.47) NPC1RAB9ALMNAALDH1A1KMT2A
SCHEMBL20914167 0.84 ARF6 (0.41) LMNAALDH1A1POLBKMT2AMEN1
SCHEMBL20914276 0.83 ALDH1A1 (0.41) NPC1RAB9AALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 NPC1 2215/4885RAB9A 2467/4885LMNA 4242/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 NPC1 2215/4885RAB9A 2467/4885LMNA 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback